Text and Data Mining valid from 2020-02-12
Received: 11 March 2019
Accepted: 16 August 2019
First Online: 12 February 2020
Compliance with ethical standards
: H-U. Kauczor reports grants, personal fees for lectures and non-financial support from Siemens, grants and personal fees for lectures from Philips, and personal fees for lectures from Boehringer Ingelheim and Bracco, outside the submitted work.A-M. Baird reports personal fees and non-financial support for meeting attendance from Roche and MSD, outside the submitted work; and is a board member for Lung Cancer Europe (LuCE); LuCE have received support from Abbvie, Amgen, BMS, Boehringer Ingelheim, Lilly, Merck, MSD, Novartis, Pfizer, Roche and Takeda, and, as board member, A-M. Baird has participated on advisory boards for BMS, Takeda and Pfizer, with the fee paid directly to LuCE.T.G. Blum has nothing to disclose.L. Bonomo has nothing to disclose.C. Bostantzoglou has nothing to disclose.O. Burghuber reports grants from Boehringer Ingelheim, GSK, AstraZeneca, Menarini, Teva, Pfizer, Chiesi, Novartis and Federal State Department of Health, non-financial support (utilities and meeting facilities) from the Municipal Department of Health in Vienna and air liquid, during the conduct of the study; and personal fees for advisory board work and lectures from Boehringer Ingelheim, AstraZeneca, Chiesi, MSD, Menarini, Roche and GSK, outside the submitted work.B. Čepická is a member of the European Lung Foundation patient advisory group.A. Comanescu reports sponsorship from Merck Romania and Bristol-Myers Squibb România, during the conduct of the study; and patient advisory panel fees from Bristol-Myers Squibb, outside the submitted work.S. Couraud reports grants, personal fees and other from Roche, grants and personal fees from AstraZeneca, during the conduct of the study; and grants and personal fees from BMS, AstraZeneca, Lilly and Laidet Medical, grants, personal fees and other from Pfizer, Roche, Chugai, MSD and Boehringer Ingelheim, grants and non-financial support from Sysmex Innostics, grants from Novartis, Merck and Amgen, and personal fees from Exact Science, outside the submitted work.A. Devaraj has nothing to disclose.V. Jespersen has nothing to disclose.S. Morozov has nothing to disclose.I. Nardi Agmon has nothing to disclose.N. Peled reports consultancy for and honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Foundation Medicine, Guardant360, MSD, Novartis, NovellusDx, Pfizer, Roche and Takeda, outside the submitted work; and in addition, has patents WO2012023138, US20130150261 and WO/2015/059646 issued.P. Powell is an employee of the European Lung Foundation.H. Prosch reports grants from Siemens, outside the submitted work.S. Ravara has nothing to disclose.J. Rawlinson is a member of the patient advisory group of the ERS/European Lung Foundation (as a lung cancer patient) and a patient representative on the NHS England Screening advisory group; neither role is remunerated in any way.M-P. Revel has nothing to disclose.M. Silva has nothing to disclose.A. Snoeckx has nothing to disclose.B. van Ginneken reports grants and stock/royalties from Thirona, and grants and royalties from Delft Imaging Systems and MeVis Medical Solutions, outside the submitted work.J.P. van Meerbeeck has nothing to disclose.C. Vardavas has nothing to disclose.O. von Stackelberg has nothing to disclose.M. Gaga reports grants from Novartis, Chiesi, Elpen and Menarini, and personal fees from BMS and MSD, outside the submitted work.